Navigation Links
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Date:8/4/2011

alties on sales of approved products. AstraZeneca has responsibility for product commercialization, product discovery and development costs.

About the Collaboration Between AstraZeneca and Palatin Technologies

In 2007, Palatin Technologies entered into an exclusive research collaboration and license agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. Active development work by Palatin under the collaboration portion of the agreement concluded in January 2010.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com .

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby.  Such forwa
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
4. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
5. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
7. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Palatin Announces Strategic Realignment of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (UAE) (PRWEB) July 23, 2014 International ... recently announced that its biobanking project, Provia Laboratories ... to its growing Advisory Board. Scott Wolf , ... to have Dr. Vaught onboard with Provia’s ever-expanding Advisory ... expertise that Provia’s management team brings to this field, ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
(Date:7/23/2014)... efforts have made great strides in saving China,s endangered ... are over 65 giant panda reserves that have been ... efforts, just 1596 pandas remain in the wild. ... to save the panda by improving genetic diversity, avoid ... Just how are these high-profile programs doing so far? ...
(Date:7/23/2014)... (MIPT and Russian Quantum Center at Skolkovo) and ... and the Institute of Physics in Bratislava, Slovakia) ... of particles passing through an amplifier and, conversely, ... are provided in an article published in the ... , Quantum entangled particles are considered to be ...
Breaking Biology Technology:Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4
... Inc have successfully implemented Amphora,s PatentSafe solution to ... PatentSafe as a fully electronic lab notebook, with ... efficiently into today,s laboratories but it also allows ... and effectively, saving significant time previously spent on ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s Republic of ... quarter and fiscal year ended December 31,2008. , , ... -- Total revenues increased 104.0% year-over-year to $26.0 ...
... Hovione is pleased to announce,that its licensee Daiichi ... use Hovione,s TwinCaps(R) dry powder inhaler device in ... neuraminidase inhibitor active,against the influenza virus. Daiichi Sankyo ... in Japan and other Asian countries and results,are ...
Cached Biology Technology:Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 2Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 2China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 4China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 5China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 6China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 7China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 8China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 9China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 10Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza 2Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza 3
(Date:7/23/2014)... Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing of ... stock at a price to the public of $6.00 per ... option to purchase up to 1,250,000 additional shares of common ... expected to begin trading on the NYSE MKT on July ... Blair & Company, L.L.C. and JMP Securities LLC are ...
(Date:7/23/2014)... that early reading skill might positively affect later intellectual ... , was conducted by researchers at the University of ... an ability that can be improved, our findings have ... research fellow in psychology at the University of Edinburgh, ... might aid not only the growth of literacy, but ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stronger early reading skills predict higher intelligence later 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... Research from Queen,s University Belfast has revealed the 20th ... certainly associated with changes in farming practices. The ... Ireland last Tuesday (22nd June), but a recent study, ... published in the international journal Biological Conservation , ...
... U.S. Department of Energy has awarded a consortium of universities ... to $9 million over the next three years to conduct ... from algae a viable and competitive alternative to gasoline for ... funds are being supplemented by $3 million from a consortium ...
... brain, scientists can alleviate the effects of disorders such ... news. But because controlling that stimulation currently lacks ... of its therapeutic benefits for the patient over time. ... of a European consortium, is delving deep into human ...
Cached Biology News:Irish hares fall foul of modern farming trap 2DOE awards UC San Diego consortium $9 million for algal biofuels research 2A pacemaker for your brain 2
FITC~Bovine Serum Albumin...
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
Biology Products: